Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,680 | -5,407 | -45,933 | -40,669 | -34,197 |
| Depreciation Amortization | 118 | 52 | 84 | 28 | N/A |
| Other Working Capital | -2,780 | 546 | -2,531 | -1,479 | -126 |
| Other Operating Activity | 2,764 | 1,406 | 25,798 | 22,482 | 20,124 |
| Operating Cash Flow | $-6,578 | $-3,403 | $-22,582 | $-19,638 | $-14,199 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -430 | N/A | -1,042 | -899 | -706 |
| Investing Cash Flow | $-430 | $N/A | $-1,042 | $-899 | $-706 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 749 | N/A | 27,612 | 27,545 | 27,545 |
| Financing Cash Flow | $749 | $N/A | $27,612 | $27,545 | $27,545 |
| Exchange Rate Effect | -81 | 10 | -159 | -196 | -188 |
| Beginning Cash Position | 24,751 | 24,751 | 20,922 | 20,922 | 20,922 |
| End Cash Position | 18,411 | 21,358 | 24,751 | 27,734 | 33,374 |
| Net Cash Flow | $-6,340 | $-3,393 | $3,829 | $6,812 | $12,452 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,578 | -3,403 | -22,582 | -19,638 | -14,199 |
| Capital Expenditure | -430 | N/A | -1,042 | -899 | -706 |
| Free Cash Flow | -7,008 | -3,403 | -23,624 | -20,537 | -14,905 |